ReCET diabetes trial reaches 350 patients as Endogenex advances toward FDA submission
Endogenex, Inc. reported on July 8 that enrollment has been completed in its pivotal ReCET clinical study, a prospective, randomized, double-blinded and sham-controlled trial evaluating an investigational endoscopic procedure in adults with inadequately controlled type 2 diabetes. The study enrolled 350 participants across approximately 40 sites in the United States and Australia under a U.S.
